What do systematic reviews say?

Intervention not reported

The intervention may leads to higher overall grade 3 to 4 toxicity (low certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 2.57 [1.45, 4.57]
  3 studies · 1831 participants
  Low

Intervention not reported

The intervention may leads to higher grade 3 to 4 diarrhoea (low certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 2.58 [1.44, 4.64]
  5 studies · 2434 participants
  Low

Intervention not reported

The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 1.22 [0.93, 1.61]
  6 studies · 2666 participants
  Moderate

Intervention not reported

The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 67.52 [30.83, 147.85]
  4 studies · 2363 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.97 [0.73, 1.29]
  2 studies · 1187 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention probably leads to lower quality of life (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2258 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in progression‐free survival (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.03 [0.89, 1.2]
  8 studies · 2567 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  HR 1.07 [0.81, 1.43]
  2 studies · 1851 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in recurrence‐free survival (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  HR 1.23 [0.96, 1.58]
  2 studies · 1851 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in direct surgical morbidity (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  RR 1.93 [0.79, 4.71]
  2 studies · 1922 participants
  Moderate

Intervention not reported

The intervention probably leads to higher surgery‐related systemic morbidity (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  RR 3.72 [1.04, 13.27]
  2 studies · 1922 participants
  Moderate

Intervention not reported

The intervention leads to higher lymphoedema or lymphocyst (high certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  RR 8.39 [4.06, 17.33]
  2 studies · 1922 participants
  High

Mifepristone (all doses) vs placebo

Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.08 [0.04, 0.17]
  1 study · 352 participants
  Moderate

Gestrinone vs danazol

It is very uncertain whether gestrinone changes side effects: hot flushes compared with danazol (very low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.79 [0.5, 1.26]
  2 studies · 302 participants
  Very low

Gestrinone vs danazol

Gestrinone showed no clear difference in side effects: acne compared with danazol (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 1.45 [0.9, 2.33]
  2 studies · 302 participants
  Low

Gestrinone vs leuprolin

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Gestrinone vs leuprolin

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 52 participants
  Low

Gestrinone vs leuprolin

Gestrinone may leads to lower amenorrhoea compared with leuprolin (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.04 [0.01, 0.38]
  1 study · 49 participants
  Low

Gestrinone vs leuprolin

Gestrinone may leads to higher spotting or bleeding compared with leuprolin (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 22.92 [2.64, 198.66]
  1 study · 49 participants
  Low